Form 4: Cytek Biosciences COO Paul Christopher Williams Reports Stock Transactions

Chief Operating Officer Paul Christopher Williams of Cytek Biosciences, Inc. reports the vesting and subsequent sale of shares to cover tax obligations.

Summary

• Paul Christopher Williams, the Chief Operating Officer of Cytek Biosciences, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 11, 2024, 1,227 Restricted Stock Units (RSUs) vested, each representing a contingent right to receive one share of Cytek Biosciences common stock.
• Also on March 11, 2024, Williams disposed of 478 shares of common stock at a price of $7.22 per share to satisfy tax withholding obligations related to the vesting of the RSU Award.
• Following these transactions, Williams directly owns 5,317 shares of Cytek Biosciences common stock and 11,046 derivative securities (Restricted Stock Units).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedule described (2/48, 3/48, 4/48 increments) is a fairly standard approach to equity compensation, designed to incentivize long-term commitment.
• Companies like Danaher, Agilent, and Thermo Fisher Scientific also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.
• The filing provides transparency to shareholders regarding executive stock ownership.

Key Dates